Clinical Trial

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
PI requested
Summary
The purpose of the study is to examine the clinical and biological effects of 177Lu-PSMA-617 in mCRPC patients with cytopenia\[s\].
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2027-06-30 -> 2026-05-04 2026-05-09
minor Completion moved earlier: 2029-06-30 -> 2026-05-04 2026-05-09
Trial Details
NCT Number NCT07025512
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Novartis
Conditions Metastatic Castration Resistant Prostate Cancer, Cytopenia, Anemia, Thrombocytopenia
Start Date 2025-08-03
Primary Completion 2026-05-04 (estimated)
Study Completion 2026-05-04 (estimated)
Updated on ClinicalTrials.gov 2026-05-08